Advertisement
Home »

Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo

Jan 09, 2024

ABOUT THE EXPERTS

Advertisement
Advertisement